Afeyan Noubar's Form 4 filing
Evelo Biosciences, Inc. (EVLO) · filed Jun 1, 2022
- Accession no.
- 0000899243-22-020533
- Filed
- Jun 1, 2022, 7:00 PM ET
- Trade date
- May 27, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market purchases total $40.0M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Afeyan NoubarCIK 0001222012 | 10% Owner |
| Flagship Pioneering, LLCCIK 0001400240 | 10% Owner |
| Flagship Ventures Fund IV, L.P.CIK 0001503559 | 10% Owner |
| Flagship Ventures Fund IV General Partner LLCCIK 0001508051 | 10% Owner |
| Flagship Ventures Fund IV-Rx, L.P.CIK 0001590973 | 10% Owner |
| Flagship Ventures Opportunities Fund I, L.P.CIK 0001677345 | 10% Owner |
| Flagship Ventures Opportunities Fund I General Partner LLCCIK 0001725004 | 10% Owner |
| Nutritional Health LTP Fund General Partner LLCCIK 0001780951 | 10% Owner |
| Nutritional Health LTP Fund, L.P.CIK 0001780956 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 27, 2022 | Common Stock | PPurchaseAcquired | +4,383,561 | $1.46 | +$6,399,999.06 | 7,590,873 | Indirect | |
| May 27, 2022 | Common Stock | PPurchaseAcquired | +1,095,890 | $1.46 | +$1,599,999.4 | 1,887,419 | Indirect | |
| May 27, 2022 | Common Stock | PPurchaseAcquired | +1,369,863 | $1.46 | +$1,999,999.98 | 5,495,324 | Indirect | |
| May 27, 2022 | Common Stock | PPurchaseAcquired | +6,849,315 | $1.46 | +$9,999,999.9 | 8,219,791 | Indirect | |
| May 27, 2022 | Common Stock | PPurchaseAcquired | +13,698,630 | $1.46 | +$19,999,999.8 | 13,698,630 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.